ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
ImageneBio reported a first-quarter net loss of $10.6 million, or $0.95 per share, with zero revenue for the period. The company completed a $30 million private placement in April, extending its cash runway into the first quarter of 2028. On the clinical side, the Phase 2b ADAPTIVE trial for lead asset IMG-007 is progressing under an amended protocol, with topline data now expected in the fourth quarter of 2027.
Key figures
- Revenue
- 0
- Deal Value Usd
- 30000000
- Runway
- Q1 2028
- Net loss
- 10619000
- Ga expenses
- 6118000
- Rd expenses
- 5961000
- Cash position
- 117200000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.